Laddar populära aktier...
Redeye gives its preview on OssDsign’s Q1 2024 report, due on May 14.
Etteplan was able to improve its profitability during the first quarter as was expected.
Redeye provides a research update following the Q1 report published by Initiator Pharma earlier toda...
Group net sales was EUR 28m in Q1 (Nordea est. EUR 29m) meanwhile adjusted EBITDA was EUR 13m (Norde...
Apart from a slight further delay in the start of Phase I with NEX-22, the report for Q1’24 proved r...
Redeye updates on Invisio following its Q1-results which were in line with our expectations.
This year could turn out to be better than expected for Incap.
Relais' Q1 adjusted EBITA came in 13% above LSEG Data & Analytics consensus with a strong 12% y/y or...
Redeye remains positive towards Avensia following a Q1 report largely matching our forecasts.
Q1 EBITA +16% y-o-y while peers decline, 8.9% (7.9%) margin Strong start in weakened market increase...
Redeye in this note comments Neonode’s Q1’24 and the last major news around the Aequitas lawsuit.
Q1 report due Wednesday 15 May at 07:00 CEST Q1e: sales EUR 44.
Oförändrat svår marknad, men den har inte blivit sämre Med en telekommarknad som har lägre investeri...
En investering i Kinda Brave Entertainment Group AB (”Kinda Brave” eller ”Koncernen”) ger exponering...
Redeye provides a note following NeoDynamics’ Q1 2024 report.